$218.00
0.32%
Nasdaq, Nov 28, 10:04 pm CET
ISIN
US5011471027
Symbol
KRYS

Krystal Biotech, Inc. Stock price

$218.00
+28.35 14.95% 1M
+94.64 76.72% 6M
+61.34 39.15% YTD
+21.09 10.71% 1Y
+141.49 184.93% 3Y
+163.06 296.80% 5Y
+207.36 1,948.87% 10Y
+207.36 1,948.87% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-0.70 0.32%

New AI Insights on Krystal Biotech, Inc. Insights AI Insights on Krystal Biotech, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$6.3b
Enterprise Value
$5.6b
Net debt
positive
Cash
$731.1m
Shares outstanding
29.0m
Valuation (TTM | estimate)
P/E
32.7 | 42.8
P/S
16.9 | 16.2
EV/Sales
15.0 | 14.3
EV/FCF
33.8
P/B
5.6
Financial Health
Equity Ratio
89.6%
Return on Equity
9.4%
ROCE
13.8%
ROIC
34.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$373.2m | $390.3m
EBITDA
$163.2m | $153.6m
EBIT
$158.2m | $148.3m
Net Income
$198.9m | $147.6m
Free Cash Flow
$165.6m
Growth (TTM | estimate)
Revenue
54.5% | 34.3%
EBITDA
125.0% | 40.7%
EBIT
143.6% | 43.7%
Net Income
279.8% | 65.6%
Free Cash Flow
185.2%
Margin (TTM | estimate)
Gross
94.3%
EBITDA
43.7% | 39.4%
EBIT
42.4%
Net
53.3% | 37.8%
Free Cash Flow
44.4%
More
EPS
$6.7
FCF per Share
$5.7
Short interest
16.5%
Employees
275
Rev per Employee
$1.1m
Show more

Is Krystal Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Krystal Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Krystal Biotech, Inc. forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Krystal Biotech, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Krystal Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
373 373
55% 55%
100%
- Direct Costs 21 21
19% 19%
6%
352 352
57% 57%
94%
- Selling and Administrative Expenses 137 137
28% 28%
37%
- Research and Development Expense 57 57
10% 10%
15%
163 163
125% 125%
44%
- Depreciation and Amortization 4.97 4.97
35% 35%
1%
EBIT (Operating Income) EBIT 158 158
144% 144%
42%
Net Profit 199 199
280% 280%
53%

In millions USD.

Don't miss a Thing! We will send you all news about Krystal Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Krystal Biotech, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
PITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:00 am ET and host investor meetings throughout the day.
Positive
Seeking Alpha
15 days ago
Krystal Biotech is rated a buy after a strong Vyjuvek launch, but the current valuation reflects premium margins and aggressive global expansion projections. Vyjuvek's US sales growth has plateaued, but international rollouts in Europe and Japan are expected to drive further sales growth, with management targeting $1B in peak sales. KRYS pipeline catalysts include KB803 (ophthalmology), KB407 (...
Positive
Seeking Alpha
27 days ago
Krystal Biotech (KRYS) reported strong Q3 results, with Vyjuvek delivering $97.8M revenue, 96% gross margin, and a new at-home use label. KRYS's disciplined operating expenses and robust cash position support profitability, while pipeline progress in cystic fibrosis and DEB eye therapy adds optionality. The FDA's Platform Technology Designation for KRYS's HSV-1 vector accelerates development, e...
More Krystal Biotech, Inc. News

Company Profile

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Head office United States
CEO Krish Krishnan
Employees 275
Founded 2016
Website www.krystalbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today